These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21310520)

  • 1. Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction.
    Sánchez Lázaro IJ; Almenar Bonet L; Martínez Dolz L; Buendía Fuentes F; Navarro Manchón J; Agüero Ramón-Llin J; Vicente Sánchez JL; Salvador Sanz A
    Rev Esp Cardiol; 2011 Mar; 64(3):237-9. PubMed ID: 21310520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction.
    Potter B; Giannetti N; Cecere R; Cantarovich M
    J Heart Lung Transplant; 2005 Aug; 24(8):1126-8. PubMed ID: 16102455
    [No Abstract]   [Full Text] [Related]  

  • 3. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation.
    Dresske B; Zavazava N; Jenisch S; Exner B; Lenz P; El Mokhtari NE; Kremer B; Faendrich F
    Transplantation; 2003 Apr; 75(8):1286-91. PubMed ID: 12717217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
    Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Following-up of a four-dose daclizumab induction therapy without calcineurin inhibitors in a liver transplantation recipient with severe renal dysfunction: a case report.
    Zhang Y; Wen T; Yan L; Chen Z; Li B; Zeng Y
    Transplant Proc; 2008 Dec; 40(10):3819-20. PubMed ID: 19100502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
    Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
    Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure.
    González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R
    J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
    Ayub-Ferreira SM; Avila MS; Feitosa FS; Souza GE; Mangini S; Marcondes-Braga FG; Issa VS; Bacal F; Chizzola PR; Cruz FD; Bocchi EA
    Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J; Lerman M; Magee MJ; Dewey TM; Herbert M; Mack MJ
    J Heart Lung Transplant; 2005 Nov; 24(11):1863-7. PubMed ID: 16297793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial immunosuppression in liver transplant recipients with impaired renal function.
    Varo E; López A; Rivero C
    Transplant Proc; 2005 Nov; 37(9):3909-12. PubMed ID: 16386581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
    DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
    Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.
    Gustafsson F; Ross HJ; Delgado MS; Bernabeo G; Delgado DH
    J Heart Lung Transplant; 2007 Oct; 26(10):998-1003. PubMed ID: 17919619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal protective strategies in heart transplant patients.
    Cantarovich M
    Curr Opin Cardiol; 2007 Mar; 22(2):133-8. PubMed ID: 17284993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
    N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.